November 21, 2008
Home
About
Submit Press Release
PR Firms
Editors/Journalists
Search Archives
 
News Releases by Category  
News by Country  
News by MSA  
All News for Today  
Browse News by Day  
News by Trackbacks  
All Press Releases for January 19, 2006 Subscribe to this News Feed  
 

Mississippi’s First Procedure with Retisert™ May Help Save Eye Sight from Uveitis

Download this press release as an Adobe PDF document.

Mississippi's first procedure for fighting Uveitis was performed at Baptist Medical Center in Jackson.

Jackson, MS (PRWEB) January 19, 2006 -- Ophthalmologist James D. Fly, M.D., of Mississippi Retina Associates, performed Mississippi’s first procedure for treating chronic non-infectious Uveitis, a sight-threatening inflammatory disease affecting the posterior segment of the eye, at Baptist Medical Center in Jackson, Mississippi.

The procedure consists of implanting Bausch & Lomb's Retisert ™, a tiny drug reservoir designed to deliver sustained level levels of the well-known corticosteroid fluocinolone acetonide directly to the back of the eye, lasting for approximately three years.

Uveitis can be caused by a number of reasons, and can even lead to blindness
“Uveitis can be caused by a number of reasons, and can even lead to blindness,” said Dr. Fly. “Sarcoid, lupus and rheumatoid arthritis are some of the diseases leading to Uveitis , and most of the patients we will treat with Retisert are legally blind.”

One of the first patients in Mississippi to receive the implant was part of the FDA study a few years ago. This 45-year-old male has Uveitis, and its origin is unknown. Dr. Fly added the patient was excited when the FDA approved the procedure. In December 2005, this patient received the implant in both eyes a week apart from each other, and his vision continues to get better.

Dr. Fly stated it generally takes about a month for most patients to notice an improvement in their vision following the procedure. However, in clinical studies 90 percent of the patients showed improved vision. Prior to the development of the Retisert implant, treatment methods for Uveitis included only large doses of oral steroids such as prednisone or immunosuppressive therapy.

“The advantage of this treatment is it doesn’t produce the systemic complications or side effects of the other treatments,” Dr. Fly added. “It puts the medication directly on the area of inflammation. This procedure is done if a person is unable to tolerate the other treatments or if one or both of the other treatments have failed.”

The procedure can be done on virtually any adult. It is conducted as an outpatient procedure done with local anesthesia. The procedure involves making an incision in the sclera through which the tiny Retisert device is implanted. Then the pellet slowly releases the cortisone over time.

Contact the Baptist Health Line at 1-800-948-6262 or 601-948-6262 or visit www.mbhs.org.

# # #

Trackback URL: http://www.prweb.com/pingpr.php/UHJvZi1DcmFzLVpldGEtU2luZy1IYWxmLVplcm8=


See the original story at: http://www.prweb.com/releases/2006/01/prweb334575.htm
Email this story to a colleague
Printer Friendly Version
Bookmark with del.icio.us
Bookmark with Y!MyWeb
Submit to Digg
Robby Channell
Baptist Health Systems
601-974-6289
Email us Here

Baptist Health Systems
Uploaded: Jan 18, 2006
File Name: BaptistHealthSystems.JPG

If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2007, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright